High levels of nuclear and cytoplasmic TFAP2α protein were a predictor of increased overall survival and progression free survival in patients with advanced bladder cancer treated with cisplatin based chemotherapy. The gene discussed is TFAP2A; the disease is urinary bladder carcinoma.